natgillin/translations-raw huggingface dataset:
In one study in children with juvenile idiopathic arthritis aged 4 to 17 years, 43 of 69 (62%) children experienced an infection while receiving Enbrel during 3 months of the study (part 1, open-label), and the frequency and severity of infections was similar in 58 patients completing 12 months of open-label extension therapy. 
V eni študiji pri otrocih z juvenilnim idiopatskim artritisom, starih od 4 do 17 let, se je pri 43 od 69 otrok (62 %) med trimesečnim zdravljenjem z zdravilom Enbrel v času študije (prvi del, odprta) pojavila okužba.
• Hepatitis C: Tell your doctor if the child has hepatitis C. Your doctor may wish to monitor the treatment with Enbrel in case the infection worsens. 
Hepatitis C: Povejte zdravniku, če ima vaš otrok hepatitis C. Zdravnik bo morda želel spremljati zdravljenje z zdravilom Enbrel za primer, če bi se okužba poslabšala.
Enbrel 0.8 mg/kg Once Weekly (N = 106) 
50 mg 1x/teden n = 166
Setting up for an injection c. 
Priprava na injiciranje c.
Postmarketing cases of Merkel cell carcinoma have been reported very infrequently in patients treated with Enbrel. 
Pri bolnikih, zdravljenih z zdravilom Enbrel, so v obdobju trženja poročali o zelo redkih primerih karcinoma Merklovih celic.
Reactivation of hepatitis B in patients who were previously infected with the hepatitis B virus (HBV) and had received concomitant TNF-antagonists, including Enbrel, has been reported. 
Pri bolnikih, ki so kdaj že bili okuženi z virusom hepatitisa B (HBV) in so se zdravili z antagonisti TNF, vključno z zdravilom Enbrel, so poročali o reaktivaciji hepatitisa B. Poročila vključujejo tudi reaktivacijo hepatitisa B pri anti-HBc pozitivnih, vendar HBsAg negativnih bolnikih.
Enbrel is available in strengths of 10, 25 and 50 mg. 
Zdravilo Enbrel je na voljo v jakostih 10, 25 in 50 mg.
During a randomised withdrawal period, significantly more patients re-randomised to placebo experienced disease relapse (loss of PASI 75 response) compared with patients re-randomised to Enbrel. 
Med obdobjem randomiziranega prekinjanja zdravljenja se je recidiv bolezni (izguba odziva PASI 75) pojavil pri pomembno več bolnikih, ki so bili ponovno v skupini s placebom, kot pri bolnikih, ki so bili ponovno v skupini z zdravilom Enbrel.
Rare cases of pancytopenia and very rare cases of aplastic anaemia, some with fatal outcome, have been reported in patients treated with Enbrel. 
Pri bolnikih, ki so bili zdravljeni z zdravilom Enbrel, so poročali o redkih primerih pancitopenije in zelo redkih primerih aplastične anemije, tudi s smrtnim izidom.
The other ingredients are: 
Potrebujete še naslednje:
• While still in the plastic package, place the vial adaptor on top of the Enbrel vial so that the vial adaptor spike is centered within the raised circle on top of the vial stopper (see Diagram 2). 
Adapter viale pustite v plastični embalaži in ga položite na vrh viale zdravila Enbrel tako, da bo konica adapterja viale poravnana z dvignjenim delom zamaška na viali (glejte sliko 2).
• Hepatitis C: Tell your doctor if you or the child have hepatitis C. Your doctor may wish to monitor the treatment with Enbrel in case the infection worsens. 
Hepatitis C: Povejte zdravniku, če imate vi ali vaš otrok hepatitis C. Zdravnik bo morda želel spremljati zdravljenje z zdravilom Enbrel za primer, če bi se okužba poslabšala.
Radiographic progression at 12 months was significantly less in the Enbrel group than in the methotrexate group, while the combination was significantly better than either monotherapy at slowing radiographic progression (see figure below). 
Po 12 mesecih zdravljenja je bilo radiografsko napredovanje pri bolnikih, ki so jih zdravili z zdravilom Enbrel, statistično pomembno počasnejše kot pri bolnikih, ki so jih zdravili z metotreksatom; kombinacija obeh zdravil pa je radiografsko napredovanje upočasnila statistično pomembno učinkoviteje kot eno samo zdravilo (glejte spodnjo sliko).
Mean serum concentration profiles at steady state in treated RA patients were Cmax of 2.4 mg/l vs. 2.6 mg/l, Cmin of 1.2 mg/l vs. 1.4 mg/l, and partial AUC of 297 mgh/l vs. 316 mgh/l for 50 mg Enbrel once weekly (n=21) vs. 25 mg Enbrel twice weekly (n=16), respectively. 
Pri bolnikih z revmatoidnim artritisom so bile povprečne koncentracije v serumu v stanju dinamičnega ravnovesja naslednje: pri zdravljenju z zdravilom Enbrel v odmerku 50 mg enkrat na teden (n = 21) je vrednost Cmax znašala 2,4 mg/l, vrednost Cmin 1,2 mg/l, delna AUC pa 297 mg·h/l, pri zdravljenju z zdravilom Enbrel v odmerku 25 mg dvakrat na teden (n = 16) pa je vrednost Cmax znašala 2,6 mg/l, vrednost Cmin 1,4 mg/l, delna AUC pa 316 mg·h/l.
The needle cover of the pre-filled syringe contains latex (dry natural rubber) that may cause hypersensitivity reactions when handled by, or when Enbrel is administered to, persons with known or possible latex sensitivity. 
Pokrovček igle napolnjene injekcijske brizge vsebuje lateks (posušen naravni kavčuk), ki lahko povzroči preobčutljivostne reakcije, če z zdravilom Enbrel ravna oseba z znano ali možno preobčutljivostjo na lateks ali če ga damo taki osebi.
Doses of 10 mg or 25 mg Enbrel were administered subcutaneously (SC) twice a week for up to 24 months. 
Odmerki 10 mg ali 25 mg zdravila Enbrel so bili dani subkutano (s.c.) 2-krat tedensko do 24 mesecev.
Physicians should exercise caution when considering the use of Enbrel in patients with a history of recurring or chronic infections or with underlying conditions that may predispose patients to infections, such as advanced or poorly controlled diabetes. 
Zdravniki morajo biti zelo previdni, kadar se odločajo za zdravljenje s tem zdravilom pri bolnikih s ponavljajočimi se ali kroničnimi okužbami v anamnezi ali z drugimi osnovnimi stanji (kot je na primer napredovala ali neurejena sladkorna bolezen), ki bi lahko povečala dovzetnost bolnikov za okužbe.
After taking a pre-filled pen from the refrigerator, wait approximately 15-30 minutes to allow the Enbrel solution in the pen to reach room temperature. 
Ko napolnjeni peresnik vzamete iz hladilnika, počakajte približno 15 do 30 minut, da se raztopina zdravila Enbrel v peresniku segreje na sobno temperaturo.
Each vial of Enbrel 10 mg powder and solvent for solution for injection for paediatric use contains 10 mg of etanercept. 
Ena viala zdravila Enbrel 10 mg prašek in vehikel za raztopino za injiciranje za uporabo pri otrocih vsebuje 10 mg etanercepta.
Studies have not been done in patients with juvenile idiopathic arthritis to assess the effects of continued Enbrel therapy in patients who do not respond within 3 months of initiating Enbrel therapy. 
Pri bolnikih z juvenilnim idiopatskim artritisom, ki se v 3 mesecih po uvedbi zdravljenja z zdravilom Enbrel ne odzovejo na zdravljenje, niso izvedli študij za ovrednotenje učinka kontinuiranega zdravljenja z zdravilom Enbrel.
A dose response was seen; results with 10 mg were intermediate between placebo and 25 mg. Enbrel was significantly better than placebo in all components of the ACR criteria as well as other measures of rheumatoid arthritis disease activity not included in the ACR response criteria, such as morning stiffness. 
Rezultati za zdravilo Enbrel so bili statistično pomembno boljši od placeba po vseh kriterijih ACR, prav tako pa tudi po tistih merilih aktivnosti revmatoidnega artritisa, ki v kriterije odziva po ACR niso vključeni, na primer jutranja okorelost.
In general, the adverse events in paediatric patients with juvenile idiopathic arthritis were similar in frequency and type to those seen in adult patients. 
Na splošno so bili neželeni učinki pri otrocih z juvenilnim idiopatskim artritisom po vrsti in pogostnosti podobni tistim pri odraslih.
Preparing the Enbrel dose for injection 
Priprava odmerka zdravila Enbrel za injiciranje
Powder: Mannitol (E421), sucrose, and trometamol. 
Pomožne snovi so: prašek: manitol (E421), saharoza in trometamol.
What Enbrel contains 
Kaj vsebuje zdravilo Enbrel
Responses were measured using ACR Pedi 30 , defined as ≥ 30% improvement in at least three of six and ≥ 30% worsening in no more than one of six JRA core set criteria, including active joint count, limitation of motion, physician and patient/parent global assessments, functional assessment, and erythrocyte sedimentation rate (ESR). 
Odzive so merili po lestvici ACR Pedi 30; izboljšanje je bilo določeno kot  30 % izboljšanje v vsaj treh od šestih glavnih kazalcev aktivnosti bolezni JRA in  30 % poslabšanje največ enega od šestih glavnih kazalcev aktivnosti bolezni JRA (število aktivno prizadetih sklepov, omejenost gibanja, zdravnikova splošna ocena, splošna ocena s strani bolnika ali staršev, ocena funkcionalnosti in hitrost sedimentacije eritrocitov).
Wipe the site where Enbrel is to be injected with the alcohol swab, using a circular motion. 
Mesto, kjer nameravate vbrizgati zdravilo Enbrel, s krožnim gibom obrišite z alkoholno blazinico.
There is insufficient evidence of the efficacy of Enbrel in patients with ankylosing spondylitis-like and arthritis mutilans psoriatic arthropathies due to the small number of patients studied. 
Zaradi majhnega števila proučevanih bolnikov ni zadostnih dokazov glede učinkovitosti zdravila Enbrel pri bolnikih s psoriatičnimi artropatijami, podobnimi ankilozirajočemu spondilitisu, in z artritisom mutilansom.
In study 1, the Enbrel-treated group had a significantly higher proportion of patients with a PASI 75 response at week 12 (30%) compared to the placebo-treated group (2%) (p<0.0001). 
V študiji 1 je bil v 12. tednu delež bolnikov z odzivom PASI 75 pomembno večji v skupini, zdravljeni z zdravilom Enbrel (30 %), kot v skupini, ki je dobivala placebo (2 %) (p  0,0001).
Responses of Patients with Ankylosing Spondylitis in a Placebo-controlled Trial Percent of Patients 
Odzivi bolnikov z ankilozirajočim spondilitisom v preskušanju, nadzorovanem s placebom Odstotek bolnikov
• Remove the plastic cap from the Enbrel vial. 
Z viale zdravila Enbrel odstranite plastično zaporko.
In a population pharmacokinetics analysis in ankylosing spondylitis patients, the etanercept steady state AUCs were 466 µg•hr/ml and 474 µg•hr/ml for 50 mg Enbrel once weekly (N = 154) and 25 mg twice weekly (N = 148), respectively. 
Pri analizi populacijske farmakokinetike pri bolnikih z ankilozirajočim spondilitisom so vrednosti AUC etanercepta v stanju dinamičnega ravnovesja pri uporabi zdravila Enbrel v odmerku 50 mg enkrat na teden (n = 154) znašale 466 μg·h/ml, pri uporabi zdravila Enbrel v odmerku 25 mg dvakrat na teden (n = 148) pa 474 μg·h/ml.
Thus the combined use of Enbrel and anakinra is not recommended (see sections 4.5 and 4.8). 
Ta kombinacija ni pokazala povečane klinične koristi, zato uporaba zdravila Enbrel skupaj z anakinro ni priporočljiva (glejte poglavji 4.5 in 4.8).
The efficacy of Enbrel was assessed in a randomised, double-blind, placebo-controlled study. 
Učinkovitost zdravila Enbrel je bila ugotovljena v randomizirani, dvojno slepi klinični študiji, nadzorovani s placebom.
You should allow 15 to 30 minutes for the Enbrel solution in the syringe to reach room temperature. 
Počakajte 15 do 30 minut, da se raztopina zdravila Enbrel v brizgi segreje na sobno temperaturo.
Baseline scoreb Week 52 scoreb 
DAS ocena v izhodišču ocena po 52 tednih remisija
In an analysis in which all patients who dropped out of the study for any reason were considered to have progressed, the percentage of patients without progression (TSS change ≤ 0.5) at 24 months was higher in the Enbrel in combination with methotrexate group compared with the Enbrel alone and methotrexate alone groups (62%, 50%, and 36%, respectively; p<0.05). 
V analizi, v kateri je veljalo, da je pri vseh bolnikih, ki so iz kateregakoli razloga izpadli iz študije, bolezen napredovala, je bil odstotni delež bolnikov brez napredovanja bolezni (sprememba TSS ≤ 0,5) po 12 mesecih večji v skupini z zdravilom Enbrel kot v skupini s placebom (73 % proti 47 %, p ≤ 0,001).
The MYCLIC pen contains a clear, colourless to pale yellow or pale brown solution for injection. 
Injekcijski peresnik MYCLIC vsebuje bistro, brezbarvno do bledo rumeno oziroma bledo rjavo raztopino za injiciranje.
Allergic reactions associated with Enbrel administration have been reported commonly. 
V povezavi z uporabo zdravila Enbrel so pogosto poročali o alergijskih reakcijah.
Your doctor may decide if the child needs less anti-diabetic medicine while taking Enbrel. 
Zdravnik lahko odloči, da bo otrok med jemanjem zdravila Enbrel potreboval manj zdravila za sladkorno bolezen.
• Cancer: Tell your doctor if the child has or has ever had lymphoma (a type of blood cancer) or any other cancer before the child is given Enbrel. 
Rak: Preden bo vaš otrok prejel zdravilo Enbrel, povejte zdravniku, če ima ali je vaš otrok imel limfom (vrsta krvnega raka) ali drugo obliko raka.
The needle cap of the pre-filled pen contains latex (dry natural rubber) that may cause hypersensitivity reactions when handled by or when Enbrel is administered to persons with known or possible latex sensitivity. 
Pokrovček igle napolnjenega injekcijskega peresnika vsebuje lateks (posušen naravni kavčuk), ki lahko povzroči preobčutljivostne reakcije, če z zdravilom Enbrel ravna oseba z znano ali možno preobčutljivostjo na lateks ali če ga damo taki osebi.
For rheumatoid arthritis, Enbrel is usually used in combination with methotrexate, although it may also be used alone if treatment with methotrexate is unsuitable for you. 
Pri zdravljenju revmatoidnega artritisa se zdravilo Enbrel običajno uporablja skupaj z metotreksatom.
Clinical Efficacy Results at 12 Months: Comparison of Enbrel vs Methotrexate vs Enbrel in Combination with Methotrexate in Patients with RA of 6 Months To 20 Years Duration 
Rezultati klinične učinkovitosti po 12 mesecih: primerjava med zdravilom Enbrel, metotreksatom in kombinacijo zdravila Enbrel in metotreksata pri bolnikih z RA, ki je trajal 6 mesecev do 20 let
Placing the needle on the syringe g. 
Namestitev igle na injekcijsko brizgo g.
Name and address of the manufacturers responsible for batch release Wyeth Pharmaceuticals 
Ime in naslov izdelovalcev, odgovornih za sproščanje serij
TEXT FOR PRE-FILLED SYRINGE LABEL - EU/1/99/126/013-015, EU/1/99/126/026 (25 mg Pre-filled Syringe) 
BESEDILO NA NALEPKI NAPOLNJENE INJEKCIJSKE BRIZGE - EU/1/99/126/013-015, EU/1/99/126/026 (25 mg napolnjena injekcijska brizga)
In study 4, the Enbrel-treated group had a higher proportion of patients with PASI 75 at week 12 (38%) compared to the placebo-treated group (2%) (p<0.0001). 
V študiji 4 je bil v 12. tednu delež bolnikov z odzivom PASI 75 večji v skupini, zdravljeni z zdravilom Enbrel (38 %), kot v skupini, ki je dobivala placebo (2 %) (p < 0,0001).
The instructions below explain how to use the MYCLIC pen to inject Enbrel. 
V tem navodilu je opisana uporaba injekcijskega peresnika MYCLIC za injiciranje zdravila Enbrel.
Your doctor will determine if Enbrel is an appropriate treatment. 
Zdravnik bo presodil o primernosti zdravljenja z zdravilom Enbrel.
Enbrel should be used with caution in patients with a history of hepatitis C. 
Pri bolnikih z anamnezo hepatitisa C morate Enbrel uporabljati previdno.
• Remove the needle cover by firmly pulling it straight off the syringe taking care not to touch the needle or allow the needle to touch any surfaces (see Diagram 1). 
S potegom naravnost proč od brizge odstranite pokrovček igle z injekcijske brizge in pri tem pazite, da se s prsti ne dotaknete igle in da se z iglo ne dotaknete ničesar (glejte sliko 1).
Radiographic Progression: Comparison of Enbrel vs Methotrexate in Patients with RA of <3 Years Duration 
Radiografsko napredovanje: primerjava zdravila Enbrel z metotreksatom pri bolnikih z RA, ki je trajal < 3 leta
Among patients with psoriatic arthritis who received Enbrel, the clinical responses were apparent at the time of the first visit (4 weeks) and were maintained through 6 months of therapy. 
Med bolniki s psoriatičnim artritisom, ki so prejemali zdravilo Enbrel, so bili klinični odzivi vidni že pri prvem obisku (po 4 tednih) in so se ohranjali vseh 6 mesecev zdravljenja.
Enbrel 10 mg powder and solvent for solution for injection for paediatric use is supplied as a white powder with solvent for solution for injection (powder for injection). 
Zdravilo Enbrel 10 mg prašek in vehikel za raztopino za injiciranje za uporabo pri otrocih je na voljo v obliki belega praška in vehikla za raztopino za injiciranje (prašek za injekcijo).
No treatment was given for the majority of injection site reactions in the Enbrel treatment groups, and the majority of patients who were given treatment received topical preparations, such as corticosteroids, or oral antihistamines. 
Večina bolnikov, pri katerih je zdravljenje le bilo potrebno, pa je prejela lokalna zdravila, npr. kortikosteroide, ali peroralne antihistaminike.
Cartons contain 4 vials of Enbrel, 4 pre-filled syringes of water for injections, 4 needles, 4 vial adaptors and 8 alcohol swabs. 
Ena škatla vsebuje 4 viale zdravila Enbrel, 4 napolnjene injekcijske brizge z vodo za injekcije, 4 injekcijske igle, 4 adapterje za vialo in 8 alkoholnih blazinic.
2 Alcohol swabs 
2 alkoholni blazinici
You will also need 1 ml of water for injections and a syringe to administer Enbrel 16. 
Za injiciranje zdravila Enbrel boste potrebovali tudi 1 ml vode za injekcije in injekcijsko brizgo.
Again, do not touch the needle or allow it to touch any surface. 
Pri tem zopet pazite, da se igle ne dotaknete ali z njo kam zadenete.
Do not shake the pre-filled syringe of Enbrel. 
Napolnjenih injekcijskih brizg zdravila Enbrel ne smete tresti.
Serious infections (including pneumonia, deep skin infections, joint infections, blood infection, and infections at various sites); worsening of congestive heart failure; low red blood cell count, low white blood cell count, low neutrophil (a type of white blood cell) count; low blood platelet count; skin cancer (excluding melanoma); localised swelling of the skin (angioedema); hives (elevated patches of red or pale skin that often itch); eye inflammation; psoriasis (new or worsening); inflammation of the blood vessels affecting multiple organs; elevated liver blood tests (in patients also receiving methotrexate treatment, the frequency of elevated liver blood tests is common); abdominal cramps and pain, diarrhoea, weight loss or blood in the stool (signs of bowel problems). 
Občasni (pojavijo se lahko pri največ 1 od 100 bolnikov): resne okužbe (vključno s pljučnico, globokimi okužbami kože, okužbami sklepov, okužbo krvi in okužbami na različnih mestih); poslabšanje kongestivnega srčnega popuščanja; nizko število rdečih krvnih celic, nizko število belih krvnih celic, nizko število nevtrofilcev (vrste belih krvnih celic); nizko število krvnih ploščic; kožni rak (razen melanoma); lokalizirano otekanje kože (angioedem); koprivnica (rdeče ali blede kožne spremembe nad ravnijo kože, ki pogosto srbijo); očesno vnetje; luskavica (na novo nastala ali poslabšanje obstoječe); vnetje krvnih žil, ki negativno vpliva na več organov; zvečane vrednosti jetrnih encimov pri krvnih preiskavah (pri bolnikih, ki sočasno prejemajo metotreksat, so zvečane vrednosti jetrnih encimov pri krvnih preiskavah pogoste); krči in bolečina v trebuhu, driska, izguba telesne mase ali kri v blatu (znaki težav s črevesjem).
In part 2, patients with a clinical response at day 90 were randomised to remain on Enbrel or receive placebo for four months and assessed for disease flare. 
V drugem delu študije pa so bolnike s kliničnim odzivom na zdravilo Enbrel na 90. dan randomizirali v dve podskupini: ena je nadaljevala zdravljenje z zdravilom Enbrel, druga pa je nadaljnje štiri mesece prejemala placebo - pri obeh so ocenjevali ponoven izbruh bolezni.
Responses of Patients with Psoriatic Arthritis in a PlaceboControlled Trial Percent of Patients Placebo 
Odzivi bolnikov s psoriatičnim artritisom v preskušanju, nadzorovanem s placebom Odstotek bolnikov Placebo Zdravilo Enbrel
Melanoma and non-melanoma skin cancer (NMSC) have been reported in patients treated with TNF-antagonists, including Enbrel. 
Pri bolnikih, zdravljenih z antagonisti TNF, vključno z zdravilom Enbrel, so poročali o melanomu in nemelanomskem kožnem raku (NMSC- Non-Melanoma Skin Cancer).
Step 3: Injecting the Enbrel solution 
Korak 3: Injiciranje raztopine zdravila Enbrel
Patients received Enbrel 0.8 mg/kg (up to 50 mg) or placebo once weekly for 12 weeks. 
Bolniki so 12 tednov enkrat na teden prejemali zdravilo Enbrel v odmerku 0,8 mg/kg (do 50 mg) ali placebo.
If any of the following happen, do not inject more Enbrel. 
Če se pojavi karkoli od naslednjega, zdravila Enbrel ne smete več uporabljati.
24 MYCLIC pre-filled pens 24 alcohol swabs 
24 napolnjenih injekcijskih peresnikov MYCLIC 24 alkoholnih blazinic
• Hepatitis B: Tell your doctor if the child has or has ever had hepatitis B. Your doctor should test for the presence of hepatitis B infection before the child begins treatment with Enbrel. 
Hepatitis B: Povejte zdravniku, če ima ali je vaš otrok kdaj imel hepatitis B. Preden se bo vaš otrok začel zdraviti z zdravilom Enbrel, mora zdravnik opraviti test prisotnosti okužbe s hepatitisom B. Pri bolnikih, ki so kdaj že bili okuženi z virusom hepatitisa B, lahko zdravljenje z zdravilom Enbrel povzroči ponoven zagon hepatitisa B. V takem primeru morate zdravilo Enbrel prenehati uporabljati.
Carefully dispose of any Enbrel solution that has not been injected within 6 hours. 
Raztopino zdravila Enbrel, ki je v 6 urah po pripravi niste injicirali, previdno zavrzite.
Continued durable responses have been seen for up to 10 years in open-label extension treatment trials when patients received Enbrel without interruption. 
Dolgotrajna odzivnost na neprekinjeno zdravljenje z zdravilom Enbrel je bila v odprtih podaljšanih kliničnih preskušanjih potrjena za obdobja do 10 let.
Serious and fatal infections have been reported during use of Enbrel; reported pathogens include bacteria, mycobacteria (including tuberculosis), viruses and fungi. 
Med povzročitelji, o katerih so poročali, so bile bakterije, mikobakterije (vključno s tuberkulozo), virusi in glivice.
Antibodies to Enbrel 
Protitelesa proti zdravilu Enbrel
2 pre-filled syringes 2 alcohol swabs 
2 napolnjeni injekcijski brizgi 2 alkoholni blazinici
Int erst it ial lung disease (including pneumonitis and pulmonary fibrosis)* 
Bolezni dihal, prsnega koša in mediastinalnega prostora intersticijska bolezen pljuč (vključno s pnevmonitisom in pljučno fibrozo)*
CNS demyelinating events suggestive of multiple sclerosis or localised demyelinating conditions, such as optic neuritis and transverse myelitis (see section 4.4), peripheral demyelinat ing event s, including GuillainBarré syndrome, chronic inflammatory demyelinating polyneuropathy, demyelinating polyneuropat hy, and multifocal motor neuropathy (see section 4.4), seizure 
Bolezni živčevja demielinizirajoči pojavi v CŽS, ki kažejo na multiplo sklerozo, ali lokalizirana demielinizirajoča stanja, kot sta optični nevritis in transverzni mielitis (glejte poglavje 4.4), demielinizacija perifernega živčevja, vključno z GuillainBarréjevim sindromom, kronično vnetno demielinizirajočo polinevropatijo, demielinizirajočo polinevropatijo in multifokalno motorično nevropatijo (glejte poglavje 4.4), epileptični napad
For patients who test positive for HBV infection, consultation with a physician with expertise in the treatment of hepatitis B is recommended. 
Če je bolnik pozitiven na HBV, je pred uvedbo zdravljenja z zdravilom Enbrel priporočljivo posvetovanje z zdravnikom specialistom za zdravljenje hepatitisa B. Pri dajanju zdravila Enbrel bolnikom, ki so že bili okuženi s
Among patients with ankylosing spondylitis who received Enbrel, the clinical responses were apparent at the time of the first visit (2 weeks) and were maintained through 6 months of therapy. 
Med bolniki z ankilozirajočim spondilitisom, ki so prejemali zdravilo Enbrel, so bili klinični odzivi vidni že pri prvem obisku (po 2 tednih) in so se ohranjali ves čas 6 mesecev zdravljenja.